In 2006, a landmark article on personalized chemotherapy for lung cancer was published in the New England Journal of Medicine, which indicated that only patients with low expression of excision repair cross complementation 1 (ERCC1) benefit from adjuvant chemotherapy (7). Here, ERCC1 is linked to lung cancer.